This will take effect April 14, 2014
Overview and Clinical Utility:
Effective April 14, 2014, PathGroup will be changing methodology for cardiolipin antibodies IgA, IgG and IgM from enzyme immunoassay to multiplex flow immunoassay. We will also insource Beta-2 Glycoprotein IgA, IgG and IgM using multiplex flow immunoassay.
Click Here to read more.